Katelin’s Turn is HERE!!!, page-148

I think I probably speak for many of us here Mel in that it is yours and Katelin’s BRAVERY in persevering and seeking that optimal therapeutic dose that is so inspiring.

I work in health here in Australia, primarily with adults with neurological conditions such as Parkinson’s Disease and dementia. The confounding impacts and secondary effects of titrating up and down medication regimes is so complex and often very demoralising. Many patients and families just give up and it’s perfectly understandable.

But certainly something like dementia sadly doesn’t have anything as promising on its horizon as Daybue is right here, right now for Rett’s.

It’s the human stories like yours and knowledge gained through your therapeutic pathways that are the true richness of being invested in a company like Neuren.

The financial gains are of course very nice, but they flow naturally from all progress made towards quality of life gains through our breakthrough treatment modalities.

And of course so, so much more to come….